Advanced development of multivalent vaccine candidates for filovirus and lassa fever
Active Definitive Contract Awarded Last action
- Contract number
- HHSN272201700082C
- Awardee
-
Thomas Jefferson University UEI R8JEVL4ULGB7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $25,993,793
Award facts
- Opportunity
-
- NIHAI2016064 Solicitation number
- Advanced Development of Multivalent Vaccine Candidates for Filovirus and Lassa Fever Award Notice · Posted Apr 29, 2016
- Contract value 96% obligated
-
- $25,993,792.86 Current, with exercised options
- $26,951,717.86 Potential, with all options
- Completion date 88% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Philadelphia, PA 19107, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$90,977 | |
| Supplemental Agreement for work within scope | -$602,730 | |
| Supplemental Agreement for work within scope | $3,347,060 | |
| Supplemental Agreement for work within scope | -$209,792 | |
| Exercise an Option | $708,766 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$1,165,424 | |
| Funding Only Action | $27,192 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $181,246 | |
| Funding Only Action | -$383,528 | |
| Exercise an Option | $589,175 | |
| Supplemental Agreement for work within scope | $392,022 | |
| Supplemental Agreement for work within scope | -$257,664 | |
| Exercise an Option | $2,802,920 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $610,747 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,272,259 | |
| Exercise an Option | $4,515,928 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,467,673 | |
| Exercise an Option | $5,316,866 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,157,689 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $2,675,364 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $2,639,002 |
Show all 31
About this award
The National Institute of Allergy and Infectious Diseases awarded a definitive cost-no-fee contract to Thomas Jefferson University on August 30, 2017, with a $26.95 million ceiling, for advanced development of multivalent vaccine candidates for filovirus and Lassa fever. No set-aside was used, and the ultimate completion date is January 31, 2028. Place of performance is Philadelphia, PA 19107.
Scope covers immunogenicity and primary platform development for rabies virus-based vaccine constructs: FILORAB 1-3, expressing Ebola, Sudan, and Marburg virus glycoproteins, and LASSARAB, expressing Lassa virus GPC. Deliverables include GMP seed lot and master virus bank production, GLA-SE engineering lots, and non-human primate immunogenicity and challenge studies. The source describes no base-plus-option structure.
Subcontractors are IDT Biologika GMBH, under a May 21, 2025 subaward for GMP master seed virus production and related development material, and University Of Maryland, College Park, under a March 23, 2025 subaward. Under the latter, the Center for Vaccine Development and Global Health furnishes personnel, facilities, and sponsorship for a clinical trial of a rabies-vectored monovalent Lassa fever vaccine in humans.
Service Contract Inventory data reports $1.4 million invoiced in FY2020, a civilian-only inventory, and $11.5 million invoiced in FY2022 against one contractor hour, a derived government-paid rate of $11,479,706.35 per hour. The prime self-performed all reported FY2022 hours, with no subcontractors reported. Cross-year comparison spanning the FY2020 coverage change is approximate.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| IDT Biologika GMBH | $8,296,135 | |
| University Of Maryland, College Park | $2,044,431 |
Quick answers
Who was awarded contract HHSN272201700082C?
HHSN272201700082C was awarded to Thomas Jefferson University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 30, 2017.
How much is contract HHSN272201700082C worth?
The government has obligated $25,993,793 on HHSN272201700082C. Its potential value, with all options, is $26,951,718.
Was contract HHSN272201700082C competed?
The extent of competition for HHSN272201700082C was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award